Publications - please follow the hyperlinks in order to access the (open access) full texts

Miesbach W, Menne J, Bommer M, Schönermarck U, Feldkamp T, Nitschke M, Westhoff TH, Seibert FS, Woitas R, Sousa R, Wolf M, Walzer S, Schwander B. Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study. Orphanet J Rare Dis. 2019 Nov 15;14(1):260. doi: 10.1186/s13023-019-1240-0.

Schwander B, Feldstein J, Sulo S, Gonzalez LMF, Hassany M: Pursuing elimination of hepatitis C in Egypt - an economic evaluation of a country-wide program and its associated cost-effectiveness. 22nd ISPOR Annual European Congress, Copenhagen, Denmark, 5th November 2019 (PIN71).

 

Feldstein J, Schwander B, Roberts M, Coussons H: Cost of ownership assessment for a da Vinci robot based on US real-world data. Int J Med Robot. 2019 Jun 19:e2023. doi: 10.1002/rcs.2023

 

Schwander B, Nuijten M, Hiligsmann M, Queally Q, Leidl R, Joore M; Oosterhoff M, Frew E, van Wilder P, Postma M, Evers S: Identification and Expert Panel Rating of Key Structural Approaches applied in Health Economic Obesity Models. Presentation at the 11th annual conference of the German Society of Health Economics (DGGÖ), Augsburg, Germany, March 19th 2019.

Miesbach W; Menne J, Bommer M; Schonermarck U; Feldkamp T, Nitschke M, Westhoff T; Seibert F; Woitas R; Sousa R, Wolf M, Walzer S, Schwander B: Incidence of acquired thrombotic thrombocytopenic purpura episodes in adults in Germany: Results of a hospital level study and projection to national estimates. Presentation at the 63rd Annual Meeting of the Society of Thrombosis and Haemostasis Research (GTH), Berlin, Germany, February, 27th to March, 2nd  2019.

 

Schwander B., Nuijten M, Hiligsmann M, Evers S. Event simulation and external validation applied in published health economic models for obesity: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research, 2018, DOI: 10.1080/14737167.2018.1501680

 

Schwander B, Charter R, Facey K, Nneka C: Mind the gap: how should we manage the difference between regulatory and reimbursement evidence requirements for medical devices? 20th ISPOR Annual European Congress, Glasgow, Scotland, 6th November 2017 (IP7).

Schwander B, Nuijten M, Hiligsmann M, Evers S: Quantity and quality of external event validation procedures performed in published health economic models in obesity: outcomes of a systematic review. 20th ISPOR Annual European Congress, Glasgow, Scotland, 8th November 2017 (PRM131).

Robson E, Schwander B, Zoellner YF: Cost-utility analysis of physicians’ guideline adherence for osteoporosis in Germany. 20th ISPOR Annual European Congress, Glasgow, Scotland, 6th November 2017 (PMS55).

Sulo S, Feldstein J, Partridge J, Schwander B, Sriram K, Summerfelt T:Budget Impact of a Comprehensive Nutrition-Focused Quality Improvement Program for Malnourished Hospitalized Patients. American Health & Drug Benefits. 2017 Jul Vol 10, No 5.

Schwander B, Nuijten M, Hiligsmann M, Evers S. Evaluation methodischer Vorgehensweisen zur Simulationen klinischer Ereignisse im Kontext der Prävention und Behandlung der Adipositas [Evaluation of methodological variations in the event simulation approaches of published health economic models in the context of obesity therapy and prevention]. Presentation at the 9th annual conference of the German Society of Health Economics (DGGÖ), Basel, Switzerland, March 10th 2017.

Schwander B, Nusser D, Kaier K, Walzer S.Gesundheitstechnologiebewertung (HTA) im Krankenhaus – Einführung, Praxiseinblick und Diskussion [Hospital based HTA – introduction,practical insights and discussion]. Presentation at the 9th annual conference of the German Society of Health Economics (DGGÖ), Basel, Switzerland, March 10th 2017.

Walzer S, Helfrich J, Schwander B, Martini O, Schumacher H, Dröschel D. Nutzenbewertung für innovative Hochrisiko NUBs: Eine Bestandsaufnahme[Benefit assessment for innovative high risk NUBs: a stock-taking]. Presentation at the 9th annual conference of the German Society of Health Economics (DGGÖ), Basel, Switzerland, March 10th 2017.

Schwander B, Nuijten M, Hiligsmann M, Evers S: Evaluation of methodological variations in the event simulation approaches of published health economic models in obesity prevention and therapy. 19th ISPOR Annual European Congress, Vienna, Austria, 31st October 2016 (PRM102).

Schwander B, Hiligsmann M, Nuijten M, Evers S: Systematic review and overview of health economic evaluation models in obesity prevention and therapy. Expert Rev Pharmacoecon Outcomes Res. 2016 Sep 9:1-10.

Schwander B, Hiligsmann M, Nuijten M, Evers S: Systematic review and overview on health economic evaluation models in the context of obesity therapy and prevention. Poster presentation at the European Health Economic Association (EuHEA), Hamburg, Germany, July 15th 2016.

Walzer S, Schwander B, Gutknecht M, Dröschel D, Steinhauser C, Gottschalk G. Nutzenbewertung für Hochrisiko-Medizinprodukte -eine systematische Methodenbewertung [Benefit assessment for high risk medical devices – a systematic methodolgy appraisal]. Presentation at the 8th annual conference of the German Society of Health Economics (DGGÖ), Berlin, Germany, March 15th 2016.

Schwander B, Hiligsmann M, Nuijten M, Evers S: Systematische Übersichtsarbeit zu gesundheitsökonomischen Evaluationen im Kontext der Behandlung und Prävention der Adipositas. Short presentation and poster at the 8th annual conference of the German Society of Health Economics (DGGÖ), Berlin, Germany, March 15th 2016.

Schwander B: Untersuchung des gesundheitsökonomischen Potentials der nächsten Generation prothetisch-optischer Systeme zur Behandlung der Blindheit in Deutschland: Eine frühe Kosten-Nutzen Bewertung. [Early health economic evaluation of the future potential of next generation artificial vision systems for treating blindness in Germany: An early cost-utility assessment]. Oral Presentation at the 7th annual conference of the German Society of Health Economics (DGGÖ), Bielefeld, Germany, March 16th 2015.

Dröschel D, Walzer S: Schwander B: Gibt es Gemeinsamkeiten in den Anforderungen der Kostenträger und Prozessen der Erstattungswege für  Medizinprodukte in den DACH Regionen (Deutschland, Österreich und Schweiz)? [Are there any commonalities in payer requirements and reimbursement pathways for medical devices in the DACH (Germany, Austria, Switzerland) region?] Oral Presentation at the 7th annual conference of the German Society of Health Economics (DGGÖ), Bielefeld, Germany, March 16th 2015.

Schwander B, Akmaz B, Werner C, Kessel-Steffen M.  Prescription analysis and comparison of daily therapy costs of Abilify Maintena to previous atypical depot-antipsychotics in clinical practice [Verordnungsanalyse und Vergleich der Tagestherapiekosten von Abilify Maintena zu bisherigen atypischen Depot-Antipsychotika im klinischen Alltag].  Poster Presentation at the Annual Congress of the German Association for Psychiatry, Psychotherapy and Psychosomatics, Berlin, Germany, 27th November 2014 (P-05-006).

Janetzky W, Schwander B, Akmaz B, Werner C, Kessel-Steffen M.  Cost analysis of Abilify Maintena (Aripiprazole-Depot) after therapy change from oral Abilify (Aripiprazol-Oral) in Germany [Kostenanalyse von Abilify Maintena (Aripiprazol Depot) nach Therapieumstellung von oralem Abilify (Aripiprazol-Oral) in Deutschland].  Poster Presentation at the Annual Congress of the German Association for Psychiatry, Psychotherapy and Psychosomatics, Berlin, Germany, 28th November 2014 (P-06-010).

Schwander B, Banz K, Kaier K, Walzer S: Is it possible to predict the market access of a new pharmaceutical in Germany? A systematic evaluation of Federal Joint Committee decisions on the early benefit assessments according to the German law for reforming the market of pharmaceuticals. 17th ISPOR Annual European Congress, Amsterdam, The Netherlands, 10th November 2014 (PHP199).

Schwander B: The future health economic potential of next generation artificial vision devices for treating blindness in Germany: An early cost utility assessment. 17th ISPOR Annual European Congress, Amsterdam, The Netherlands, 11th November 2014 (PSS35).

Walzer S, Droeschel D, Hentschel D, Waage F, Portegies W, Schwander B: Are there any commonalities in payer requirements and reimbursement pathways for medical devices in the DACH (Germany, Austria, Switzerland) region? 17th ISPOR Annual European Congress, Amsterdam, The Netherlands, 10th November 2014 (PHP59).

Schwander B: Early health economic evaluation of the future potential of next generation artificial vision systems for treating blindness in Germany. Health Economics Review. 2014. 4:27.

Schwander B, Banz K, Kaier K, Walzer S: Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal products. 2014 Sep;117(3):334-44.http://dx.doi.org/10.1016/j.healthpol.2014.07.002.

Lee VWY, Schwander B, Lee VHF:  Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor–activating mutation-positive non–small-cell lung cancer patients in Hong Kong. Hong Kong Med J 2013;19: Epub 2013 Nov 22  DOI: 10.12809/hkmj13398.

Schwander B, Krone FA, Walzer S: Clinical and Health Economic Evidence Requirements for obtaining Health Insurance Coverage for Innovative Medical Devices in Germany. 16th ISPOR Annual European Congress, Dublin, Ireland, November 2013 (PHP127).

De Madaria E, Gonzalez-Carro P, Boadas J, Puig de la Bellacasa J, Carr E, Labrador E, Paz S, Lizán L, Schwander B, Dominguez Muñoz E: Diagnosis of Pancreatic Exocrine Insufficiency in Chronic Pancreatitis, Pancreatic Cancer and Gastrointestinal or Pancreatic Surgery Patients: A Systematic Review and Expert Consensus on the Accuracy of Diagnostic Tests used in Spain. 16th ISPOR Annual European Congress, Dublin, Ireland, November 2013 (PGI 3).

Walzer S, Kogels E, Schwander B, Nuijten M:Pharmaceutical premium price strategy: What could be applied by the medical nutrition industry? Agro-Food-Industry, Supplement 24:2 2013.

Schwander B, Banz K, Walzer S: Untersuchung der Prädiktierbarkeit von Entscheidungen des GBA zur frühen Nutzenbewertungen gemäß AMNOG - ein systematischer Ansatz am Beispiel onkologischer Arzneimittel [Evaluation of the potential prediction of G-BA decisions on the early benefit assessment according to AMNOG – a systematic approach using the example of oncology drugs]; Oral Presentation (Session 5) at the 5th annual conference of the German Society of Health Economics (DGGÖ), Essen, Germany, March 12th 2013.

Schwander B, Banz K, Walzer S:The Quest for the Holy Grail: The potential prediction of GBA decisions on early benefit assessments according to AMNOG - a systematic approach. poster presentation (P26) at the BioValley Science Day, Basel, Switzerland, September 25th 2012.

Schwander B, Simona R, Giuliani G, Nuijten Mark, Walzer S:  Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy; Clinicoecon Outcomes Res. 2012;4:237-47. Epub Sep 2012.

 Lee VWY, Lee V, Schwander B: Comparative Effectiveness and Cost-Effectiveness Assessment of Erlotinib versus Gefitinib in First-Line Treatment of EGFR Activating Mutation Positive Non-Small Cell Lung Cancer for Hong Kong; poster presentation (PCN21) at the ISPOR 5th Asia Pacific Conference, Taipei, Taiwan, September 2012.

Schwander B, Chouaid C, Vergnenegre A, Bischoff HG, Nuijten M, Siebert U, Walzer S: From Indirect Evidence to Direct Evidence: A Real-World Example for the Value of Indirect Treatment Comparisons in Second-Line NSCLC Therapy.17th ISPOR Annual Meeting, Washington, DC, USA, June 2012 (PCN9).

Schwander B, Ravera S, Giuliani G,  Nuijten M, Walzer S: Cost Comparison of Erlotinib versus Generic Docetaxel in Second-Line Non-Small Cell Lung Cancer in Italy. 17th ISPOR Annual Meeting, Washington, DC, USA, June 2012 (PCN37).

Schwander B, de Castro Carpeño J, Heigener D, Wright E, Bischoff HG, Walzer S: Comparative Effectiveness Assessment of Erlotinib versus Gefitinib in First-Line EGFR Activating Mutation Positive Non-Small Cell Cancer. 16th ISPOR Annual Meeting, Baltimore, MD, USA, May 2011 (PCN7).

Mickisch GH, Schwander B, Escudier B, Bellmunt J, Maroto P, Porta C, Walzer S, Siebert U: Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy; Clinicoecon Outcomes Res. 2011;3:19-27. Epub 2011 Jan 25.

Mickisch GH, Schwander B, Cassinello JG, Carles J, Walzer S, Nuijten M: Simulation and Comparison of Progression-Free Survival Outcomes of Sequential Therapy in Metastatic Renal-Cell Carcinoma. ISPOR 13th Annual European Congress Prague, Czech Republic, November 2010 (PCN 23).

Silva CI, Monteiro I, Schwander B: Cost Analysis of Managing Adverse Events in the Treatment of Metastatic Renal Cell Carcinoma in Portugal a Comparison of Bevacizumab in Combination with Interferon Alfa-2a and Sunitinib. ISPOR 13th Annual European Congress Prague, Czech Republic, November 2010 (PCN 40).

Mickisch GH, Schwander B, Escudier B, Bellmunt J, Maroto P, Porta C, Walzer S, Siebert U: A comparative effectiveness assessment of first-line bevacizumab + interferon alpha-2 vs sunitinib in metastatical renal cell carcinoma. ISPOR 12th Annual European Congress, Paris, France, October 2009 (PCN 13).

Schwander B, Mickisch GH, Walzer S, Siebert U: Methodological issues of control arm adjustments for comparative effectiveness assessments: An example based on the comparison of first-line bevacizumab+interferon alpha-2a vs sunitinib in renal cell carcinoma. ISPOR 12th Annual European Congress, Paris, France, October 2009 (CN8).

Mickisch GH, Schwander B, Walzer S: Metastatic renal cell carcinoma: A comparative effectiveness assessment of first-line bevacizumab+interferon alpha-2a vs sunitinib. European Society for Medical Oncology Conference, Berlin, Germany, September 2009 (P159).

Schwander B, Gradl B, Zöllner Y, Lindgren P, Diener HC, Lüders S, Schrader J, Villar FA, Greiner W, Jönsson B: Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe - The Health Model; Value in Health 2009 Vol 12 (6): 857-870.

Schwander B, Lindgren P, Gradl B: The cost-effectiveness (cost-utility) of eprosartan in hypertensive patients with cerebrovascular disease in Belgium, Germany, Spain, UK, and Sweden. ISPOR 10th European Congress, Dublin, Ireland, October 2007 (CV8).

Schwander B, Haller H. Eprosartan - Gesundheitsökonomische Betrachtung; Antihypertensive Schlaganfallprophylaxe und gesundheitsökonomische Aspekte; German Society for Internal Medicine; 113th Annual Meeting , Wiesbaden, Germany, April 2007

Lindgren P, Schwander B, Zöllner Y, Jönsson B: Cost-utility analysis of Eprosartan compared to Enalapril and Ramipril in the treatment of moderate to severe hypertension in Sweden. ISPOR 9th European Congress, Copenhagen, Denmark, October 2006 (PCV53).

Mueller E, Schwander B, Bergemann R: Use of Capsule Endoscopy in Diagnosing Obscure Gastrointestinal Bleeding: Cost-Effectiveness Evaluation from a European Perspective. ISPOR 7th European Congress, Hamburg, Germany, October 2004 (PGI4).

Mueller E, Schwander B, Bergemann R. Cost-effectiveness evaluation for a new diagnostic test considering also costs for false negative and false positive diagnoses at various prevalence rates. ISPOR 7th European Congress, Hamburg, Germany, October 2004 (PGI14).

Mueller E; Schwander B; Zerwes U, Bergemann R: HTA Bericht: Klinische und ökonomische Evaluation des diagnostischen Verfahrens "Kapselendoskopie" zur Untersuchung des Dünndarms. DIMDI DAHTA-Datenbank; Dokument-Nr. DAHTA107, Berichts-Nr. ANALYTICA002, September 2004.

Mueller E, Schwander B, Bergemann R: Evaluation of cost-effectiveness for diagnostic tests when no gold standard is available in routine. In: ESMDM, European Society for Medical Decision Making 9th Biennial Conference, Rotterdam, Netherlands, June 2004.

Mueller E, Schwander B, Bergemann R: Cost-effectiveness of Capsule Endoscopy in Diagnosing Obscure Gastrointestinal Bleeding from a European Perspective. ESMDM, European Society for Medical Decision Making 9th Biennial Conference, Rotterdam, Netherlands, June 2004.

Mueller E, Schwander B, Bergemann R: Cost-Effectiveness of Capsule Endoscopy in Diagnosing Obscure Gastrointestinal Bleeding an International Comparison. Digestive Disease Week (DDW), New Orleans, USA, May 2004.

Bergemann R, Mueller E, Schwander B: Cost Effectiveness of Capsule Endoscopy in diagnosing Obscure Gastrointestinal Bleeding in Germany, France, Switzerland, and the U.S. In: ICCE, 3rd ICCE, Miami, March 2004.

Rosery H, Schwander B, Bergemann R: Identification of Unit Costs in Rheumatoid Arthritis. Research Approach and Results; ISPOR 6th Annual European Congress, Barcelona, Spain November 2003 (PMD23).